CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies ; hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. CSL Behring operates the plasma collection network CSL Plasma. CSL Behring is a member of the Australian CSL Group of companies. Parent company CSL Limited is a specialty biopharmaceutical company headquartered in Parkville, Australia. As part of a global alignment, the CSL Behring brand was established in 2007. Previously known as ZLB Behring, the company's history dates back to 1904, when it was founded in Germany by Emil von Behring, the Nobel Prize winning inventor of serum therapy or serology.
History
In 1904, Emil von Behring founded the Behringwerke in Marburg, Germany, for the purpose of experimental work on disease prevention and for the manufacture of sera and vaccines. In 1913, Behringwerke expanded to produce a gas gangrene antiserum and a cholera vaccine. In 1916, CSL was established in Australia with the goal of providing vaccines to the people of Australia and New Zealand. In 1930, CSL released an antivenom for tiger snake bites. In 1944, CSL began producing penicillin for the military and Australia. In 1954, Australian CSL officer Val Bazeley assists Jonas Salk with the production of the experimental polio vaccine used in the first clinical trials in the US. Bazeley returns to Australia to set up production of the Salk vaccine at CSL. In 1981, Behringwerke introduced Haemate, human plasma coagulation factor VIII/von Willebrand factor complex for the treatment of patients with hemophilia A. In 1991, CSL Limited was incorporated in Australia. In 2004, CSL Limited completed the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring. In 2007, ZLB Behring became CSL Behring. In 2009, ZLB Plasma changed its name to CSL Plasma to align with its parent company, CSL Behring, and opened the plasma testing laboratories in Knoxville, Tennessee. Also in 2009, the National Organization for Rare Disorders recognized CSL Behring for developing and marketing a treatment in the U.S. for acute bleeding episodes in patients with congenital fibrinogen deficiency and the Swiss government awarded CSL Behring the Tell Award. In 2012, the European Organisation for Rare Disorders recognized CSL Behring for its work developing and manufacturing therapies used to treat rare and serious medical conditions with the 2012 EURORDIS Award.
Privigen, human polyvalent immunoglobulin, liquid 10% solution for intravenous injection
Rhophylac human anti-D immunoglobulin. Prefilled syringes of highly purified anti-Rhesus factor D IgG for intravenous administration and intramuscular injection.
Tetagam P, human tetanus immunoglobulin, liquid 16% solution for intramuscular injection
Varicellon P, human varicella immunoglobulin, liquid 16% solution for intramuscular injection
;Coagulation/bleeding disorders
Beriate, freeze-dried human coagulation factor VIII concentrate
Berinin P, freeze-dried human coagulation factor IX concentrate
